Atamyo Therapeutics, a clinical-stage biotechnology company focused on the development of new-generation gene therapies targeting muscular dystrophies and cardiomyopathies, today announced its participation in upcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).
- Five upcoming communications on LGMD programs at Myology 2024 Congress
- CEO Stephane Degove to present corporate overview at BioEquity Europe 2024
Evry, France (April 22, 2024) - Atamyo Therapeutics, a clinical-stage biotechnology company focused on the development of new-generation gene therapies targeting muscular dystrophies and cardiomyopathies, today announced its participation in upcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).
Five upcoming communications at the 8th International Myology Congress (April 22-25, 2024 in Paris, France).
Five communications describing Atamyo’s LGMD programs will be presented at the 8th International Myology Congress:
- Development of gene therapy for three prevalent forms of LGMD
- Oral Presentation by E. Giquel (Genethon), at Havane Amphitheatre, on April 24, 2024, 11h00
- Heart toxicity can be induced in rats after injection of high level of AAV expressing γ–sarcoglycan using the Desmin and MHCK7 but can be prevented by the tMCK promoter
- J Poupiot (Genethon) et al., poster number P331, Therapeutics session
- Evaluation of gene transfer efficiency in a mild model of dystrophic muscle disorder performed by machine learning and linear discriminant analysis
- A Brureau (Genethon) et al., poster number P117, Muscle Function session
- Lipid metabolism is disrupted in mouse and human models of FKRP deficiency, and rescued after FKRP gene transfer
- E Gicquel (Genethon) et al., poster number P296, Muscular Dystrophy session
- FKRP related Limb Girdle Muscular Dystrophy: A biomarker identification study
- S Campuzano (Genethon) et al., poster number P293, Muscular Dystrophy session
Atamyo to participate in BioEquity Europe Conference (May 12-14 in San Sebastian, Spain).
Stephane Degove, Atamyo CEO, will provide a corporate overview during an oral presentation on May 14, at 11:20 AM, in the Room 4+5
About Atamyo Therapeutics
Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD2I/R9 and LGMD2C/R5. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. For more information visit www.atamyo.com
U.S. Contact:
Charles Craig, Opus Biotech Communications
Charles.s.craig@gmail.com, 404-245-0591
European contact: contact@atmayo.com